These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 22440913)

  • 1. Maribavir and human cytomegalovirus-what happened in the clinical trials and why might the drug have failed?
    Marty FM; Boeckh M
    Curr Opin Virol; 2011 Dec; 1(6):555-62. PubMed ID: 22440913
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Maribavir (ViroPharma).
    Lu H; Thomas S
    Curr Opin Investig Drugs; 2004 Aug; 5(8):898-906. PubMed ID: 15600248
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Maribavir prophylaxis for prevention of cytomegalovirus disease in recipients of allogeneic stem-cell transplants: a phase 3, double-blind, placebo-controlled, randomised trial.
    Marty FM; Ljungman P; Papanicolaou GA; Winston DJ; Chemaly RF; Strasfeld L; Young JA; Rodriguez T; Maertens J; Schmitt M; Einsele H; Ferrant A; Lipton JH; Villano SA; Chen H; Boeckh M;
    Lancet Infect Dis; 2011 Apr; 11(4):284-92. PubMed ID: 21414843
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oral maribavir for treatment of refractory or resistant cytomegalovirus infections in transplant recipients.
    Avery RK; Marty FM; Strasfeld L; Lee I; Arrieta A; Chou S; Tatarowicz W; Villano S
    Transpl Infect Dis; 2010 Dec; 12(6):489-96. PubMed ID: 20682012
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Maribavir: 1263W94, Benzimidavir, GW 1263, GW 1263W94, VP41263.
    Drugs R D; 2007; 8(3):188-92. PubMed ID: 17472414
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects on maribavir susceptibility of cytomegalovirus UL97 kinase ATP binding region mutations detected after drug exposure in vitro and in vivo.
    Chou S; Hakki M; Villano S
    Antiviral Res; 2012 Aug; 95(2):88-92. PubMed ID: 22664236
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Maribavir: a novel antiviral agent with activity against cytomegalovirus.
    Trofe J; Pote L; Wade E; Blumberg E; Bloom RD
    Ann Pharmacother; 2008 Oct; 42(10):1447-57. PubMed ID: 18698013
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Maribavir antagonizes the antiviral action of ganciclovir on human cytomegalovirus.
    Chou S; Marousek GI
    Antimicrob Agents Chemother; 2006 Oct; 50(10):3470-2. PubMed ID: 17005835
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Why did maribavir fail in stem-cell transplants?
    Snydman DR
    Lancet Infect Dis; 2011 Apr; 11(4):255-7. PubMed ID: 21414844
    [No Abstract]   [Full Text] [Related]  

  • 10. Maribavir prophylaxis for prevention of cytomegalovirus infection in allogeneic stem cell transplant recipients: a multicenter, randomized, double-blind, placebo-controlled, dose-ranging study.
    Winston DJ; Young JA; Pullarkat V; Papanicolaou GA; Vij R; Vance E; Alangaden GJ; Chemaly RF; Petersen F; Chao N; Klein J; Sprague K; Villano SA; Boeckh M
    Blood; 2008 Jun; 111(11):5403-10. PubMed ID: 18285548
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interim analyses in clinical trials: why do we plan them?
    Fossâ SD; Skovlund E
    J Clin Oncol; 2000 Dec; 18(24):4007-8. PubMed ID: 11118460
    [No Abstract]   [Full Text] [Related]  

  • 12. Fast selection of maribavir resistant cytomegalovirus in a bone marrow transplant recipient.
    Schubert A; Ehlert K; Schuler-Luettmann S; Gentner E; Mertens T; Michel D
    BMC Infect Dis; 2013 Jul; 13():330. PubMed ID: 23870704
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Maribavir for Refractory or Resistant Cytomegalovirus Infections in Hematopoietic-cell or Solid-organ Transplant Recipients: A Randomized, Dose-ranging, Double-blind, Phase 2 Study.
    Papanicolaou GA; Silveira FP; Langston AA; Pereira MR; Avery RK; Uknis M; Wijatyk A; Wu J; Boeckh M; Marty FM; Villano S
    Clin Infect Dis; 2019 Apr; 68(8):1255-1264. PubMed ID: 30329038
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Maribavir use in practice for cytomegalovirus infection in French transplantation centers.
    Alain S; Revest M; Veyer D; Essig M; Rerolles JP; Rawlinson W; Mengelle C; Huynh A; Kamar N; Garrigue I; Kaminski H; Segard C; Presne C; Mazeron MC; Avettant-Fenoël V; Lecuit M; Lortholary O; Coaquette A; Hantz S; Leruez-Ville M; Ploy MC
    Transplant Proc; 2013 May; 45(4):1603-7. PubMed ID: 23726629
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antiviral activity of maribavir in combination with other drugs active against human cytomegalovirus.
    Chou S; Ercolani RJ; Derakhchan K
    Antiviral Res; 2018 Sep; 157():128-133. PubMed ID: 30040968
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Maribavir for the Management of Cytomegalovirus in Adult Transplant Recipients: A Review of the Literature and Practical Considerations.
    Kleiboeker HL; Descourouez JL; Schulz LT; Mandelbrot DA; Odorico JS; Rice JP; Saddler CM; Smith JA; Jorgenson MR
    Ann Pharmacother; 2023 May; 57(5):597-608. PubMed ID: 36003036
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Maribavir: First Approval.
    Kang C
    Drugs; 2022 Feb; 82(3):335-340. PubMed ID: 35147913
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genotypic characterization of human cytomegalovirus UL97 phosphotransferase natural polymorphism in the era of ganciclovir and maribavir.
    Boutolleau D; Burrel S; Agut H
    Antiviral Res; 2011 Jul; 91(1):32-5. PubMed ID: 21570426
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cytomegalovirus UL97 kinase mutations that confer maribavir resistance.
    Chou S; Wechel LC; Marousek GI
    J Infect Dis; 2007 Jul; 196(1):91-4. PubMed ID: 17538888
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cytomegalovirus UL97 mutations in the era of ganciclovir and maribavir.
    Chou S
    Rev Med Virol; 2008; 18(4):233-46. PubMed ID: 18383425
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.